EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II

Eines Monteagudo-Vilavedra iD, Daniel Rodrigues iD, Giorgia Vella, Susana B Bravo iD, Carmen Pena, Laura Lopez-Valverde, Cristobal Colon iD, Paula Sanchez-Pintos iD, Francisco J Otero Espinar iD, Maria L Couce iD, J Victor Alvarez iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Eines Monteagudo-Vilavedra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Metabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Mucolipidoses, Transferases (Other Substituted Phosphate Groups). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Kaertor foundation, MPS Lisosomales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucolipidosis type II is a very rare lysosomal disease affecting the UDP-GlcNAc N-acetylglucosamine-1-phosphotransferase enzyme, which catalyzes the synthesis of the targeting signal mannose 6-phosphate in lysosomal acid hydrolases. Its deficiency hinders the arrival of lysosomal enzymes to the lysosome, diminishing the multiple degradations of components that cells need to perform. Due to the low prevalence of this condition, available information is scarce. This article aims to deepen the understanding of the disease; clinical, biochemical, and proteomic data are analyzed. Three patients have been identified presenting GNPTAB pathogenic variants using whole exome sequencing. A biochemical profile for these patients has been carried out through quantification of glycosaminoglycans in urine samples and enzymatic analysis in dried blood spot (DBS) samples. Quantitative proteomic studies were performed. Results show how enzymatic assays in DBS can be used to diagnose this disease both during the neonatal period or in patients of more advanced age. Increased levels of acid sphingomyelinase, alpha-iduronidase, iduronidate 2-sulfatase, alpha-N-acetyl glucosaminidase, and beta-glucuronidase are found. Conclusion: this biochemical method could potentially improve early diagnosis. Proteomic data supporting these results reveal disrupted biochemical pathways, including the degradation of dermatan sulfate, heparan sulfate, and cellular cholesterol trafficking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucolipidosesTransferases (Other Substituted Phosphate Groups)HumansMaleFemaleProteomicsPhenotypeGlycosaminoglycansExome SequencingDried Blood Spot Testing

Stichwörter der Autor:innen

biochemistrybiomarkersearly findingslysosomal diseasesmucolipidosis II-IIIproteomic studies

Substanzen

Transferases (Other Substituted Phosphate Groups)GNPTAB protein, humanGlycosaminoglycans

Autor:innen und Institutionen

  • Metabolopathies Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Metabolic Unit, Clinical University Hospital of Santiago de Compostela, Centro de Investigaciones Biomedicas en Red de Enfermedades Raras (CIBERER), European Reference Network for Rare Hereditary Metabolic Disorders (Me…
  • Department of Forensic Sciences, Pathology, Gynecology and Obstetrics, Pediatrics, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Proteomic Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.
  • Redsamid: Red de Salud Materno Infantil y del Desarrollo, Instituto de Salud Carlos III (ISCIII), 20829 Madrid, Spain.
  • Paraquasil Platform, IDIS-Health Research Institute of Santiago de Compostela, 15706 Santiago de Compostela, Spain.

ORCID-Profile: Eines Monteagudo-Vilavedra, Daniel Rodrigues, Susana B Bravo, Cristobal Colon, Paula Sanchez-Pintos, Francisco J Otero Espinar, Maria L Couce, J Victor Alvarez

Förderung

  • Instituto de Salud Carlos III
  • Kaertor foundation
  • MPS Lisosomales
  • “Instituto de Salud Carlos III” (Plan Estatal de I+D+I 2023–2025 and European Development Regional Fund) of the Spanish Ministry of Economy and Competitiveness
  • Kertor Foundation

Zitieren

APA

Monteagudo-Vilavedra, E., Rodrigues, D., Vella, G., Bravo, S. B., Pena, C., Lopez-Valverde, L., Colon, C., Sanchez-Pintos, P., Otero Espinar, F. J., Couce, M. L., & Alvarez, J. V. (2025). Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062408

Vancouver

Monteagudo-Vilavedra E, Rodrigues D, Vella G, Bravo SB, Pena C, Lopez-Valverde L, et al. Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062408

BibTeX
@article{MonteagudoVilavedra2025,
  author = {Monteagudo-Vilavedra, Eines and Rodrigues, Daniel and Vella, Giorgia and Bravo, Susana B and Pena, Carmen and Lopez-Valverde, Laura and Colon, Cristobal and Sanchez-Pintos, Paula and Otero Espinar, Francisco J and Couce, Maria L and Alvarez, J Victor},
  title = {Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062408}
}
Kostenlos starten →